Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nature escapes in a headset: a new way to calm cancer infusions?

NCT ID NCT07755501

Symptom relief Sponsor: Dott.Claudio Sini Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This randomized trial tests whether immersive virtual reality (VR) can reduce anxiety in people with lung cancer during immunotherapy or chemo-immunotherapy infusions. Half of the 60 participants will use a VR headset showing calming nature scenes during four infusion visits, while the other half receives standard care. The study measures anxiety levels at week 9 and also looks at effects on tumor response, fatigue, pain, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Immersive virtual reality using a Meta Quest 3S headset with 360-degree nature scenes
What this could lead to
If it works, virtual reality could become a simple, drug-free way to ease anxiety during cancer infusions, improving the treatment experience for many patients.
What could go wrong
This is a small, early-stage trial, and the benefit may be modest or not generalizable. Some participants might experience cybersickness or discomfort from the headset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 months to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age older than 18 years * Diagnosis of lung cancer with an indication for intravenous immunotherapy or chemo-immunotherapy * Montreal Cognitive Assessment (MoCA) score of 26 or higher * No significant hearing impairment * No significant visual impairment * Sufficient ability to read and write in Italian Exclusion Criteria: * Use of antipsychotic medications * Epilepsy * Use of illicit drugs or alcohol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung neoplasms (D008175)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Giovanni Paolo II Hospital, Medical Oncology Unit, ASL Gallura

    Olbia, Sardinia, 07026, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.